Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor (CAR) T cell therapy targeting B-cell maturation antigen (BCMA) on myeloma cells. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.